Trials for Sputnik V vaccine starts in Kanpur next week

There is relief news for India to deal with the ever-rising COVID-19 cases in the country. The first batch of the Russian Sputnik V vaccine will arrive at Ganesh Shankar Vidyarthi Medical College in Kanpur next week where there is a human clinical trial of the second and third phases of the vaccine.
According to the Press Trust of India (PTI), Dr. Reddy’s Laboratories has taken the approval of the Drug Controller General of India (DCGI) to conduct the human clinical trial.
The principal of Ganesh Shankar Vidyarthi Medical College, RB Kamal told that the human clinical trial will start from next week. For this, 180 volunteers have registered. Here, head of research Saurabh Aggarwal will decide the dose of the vaccine. After a single dose, the condition of the volunteer will be monitored and it will be seen whether they are given the next dose.
RB Kamal stated that the condition of the volunteer would be periodically checked and the data received would be analyzed to see if the vaccine was successful or not. This test will be done for seven months. After seeing the effect of vaccines in a month, the authorities will take further decisions. The Ethics Committee of the college has also given permission for the trial. This vaccine is kept at a temperature of minus 20 to minus 70 degrees Celsius.
In September, Dr. Reddy Company partnered with the Russian Director Investment Fund, Russia Sovereign Wealth Fund, to distribute Russia’s vaccine Sputnik V in India. There is an agreement to supply 10 million doses of vaccine to India after successful trials.

Sushil Modi may not be joining the govt. for the first time.

Trump acknowledges Biden’s victory for the 1st time, refuses to concede

Aamir Khan

Aamir Khan is a student at the Centre for Chinese and South-east Asian Studies, JNU, New Delhi. He also works with Hasratein- a Delhi based queer collective. The current area of his academic interest lies in the study of the Chinese language and society.